Shelter Pharma's Q1 exports hit ₹5 cr, nearly matching FY26 full year
Q1 FY27 exports have already surpassed ₹5 crores, close to the ₹6 crores earned in all of FY26. The nano-cap also targets ₹200 crore revenue by FY30 with aggressive expansion.
— 2 earlier stories on Shelter Pharma Ltd. →What's new
- Exports in Q1 FY27 surpassed ₹5 crores, nearly equalling FY26's full-year export revenue of ₹6 crores.
- FY26 revenue surged 44% to ₹73.13 crores; net profit stood at ₹9.03 crores.
- Management targets ₹200 crore revenue by FY30, with pan-India expansion and a new Ahmedabad facility.
Why this matters
For a nano-cap with a market cap of ₹47 crores, quarter-one exports alone matching nearly the entire previous year's export revenue is a step-change. The trade-off is near-term margin pain – EBITDA dipped to 17% from 20-21% as the company invests in sales and distribution. If the ₹200 crore FY30 target is met, revenue would nearly triple, but the road involves capex of ₹12-15 crores and working capital improvement from 234 days to 60-30 days.
What we're watching
- Whether export momentum can sustain as new orders from Sudan and elsewhere flow in.
- EBITDA margin recovery trajectory from 17% back to 22-25% over the next 2-3 years.
- Progress on state expansion from 15 to 30 states and utilisation of the new Ahmedabad plant.
The full read
Shelter Pharma's post-results concall on June 19 delivered one standout number: ₹5 crores in Q1 FY27 exports, almost matching the ₹6 crores earned in all of FY26. For a ₹47 crore market-cap company, that is a dramatic acceleration. FY26 revenue of ₹73.13 crores grew 44% YoY, with net profit at ₹9.03 crores. The catch is EBITDA margin pressure – 17% versus the historical 20-21% – as management spends on sales team expansion and distribution. The longer-term target: ₹200 crores by FY30, driven by a move from 15 states to all 30, a ₹12-15 crore Ahmedabad plant, and higher-margin exports. Working capital at 234 days needs to come down to 60-30 days. For a nano-cap, the visibility is above average, but execution on state expansion and margin recovery will determine whether the ₹200 crore target is a stretch or a milestone.
Questions answered
- Why are exports accelerating so sharply?
- The company has secured specific export orders, such as the ₹1.18 crore Sudan order for Joemega Capsules. Higher export margins (20-25% premium over domestic) add to the incentive.
- What caused the EBITDA margin compression?
- Management attributed the fall from historical 20-21% to 17% to deliberate spending on scaling the sales team and building distribution channels. This is an investment for future growth.
- How will the ₹200 crore FY30 target be achieved?
- Through pan-India expansion from 15 to all 30 states, a new manufacturing facility near Ahmedabad with ₹12-15 crore capex, and leveraging government procurement schemes like KPKB.
- What is the working capital situation?
- Working capital days stood at 234, but management plans to reduce credit terms to 60-30 days. Improvement here could free up cash and support growth.
- What are the key products driving growth?
- Shelter Pharma has 300 Ayurvedic formulations, with hero products including Lemonate Barley Water and Jo-Mega. Exports are led by Joemega Capsules.
- Is the FY30 target realistic given the current scale?
- FY26 revenue was ₹73 crores, so ₹200 crores in four years implies a CAGR of roughly 28%. While ambitious, the export acceleration and domestic expansion provide a credible path.
Shelter Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on SHELTER →- 19 Jun 2026 · 5:25 PM IST Shelter Pharma's Q1 exports hit ₹5 cr, nearly matching FY26 full year
- 28d ago Shelter Pharma starts shipping ₹1.18 cr Sudan order
- 34d ago Shelter Pharma locks in Gujarat manufacturing licence through 2030